Ezra Hub Physician Platform
Platform for physicians to access and review patient scan results
Company profile
Company profile
Ezra is a consumer-focused medical imaging company that provides advanced MRI and CT screening services for early detection of cancer and other serious health conditions. The company has united with Function to offer comprehensive preventive health screening that goes beyond traditional reactive healthcare. Ezra's flagship MRI scan examines up to 13 organs—including the brain, thyroid, liver, gallbladder, pancreas, spleen, kidneys, adrenal glands, bladder, ovaries, uterus, and prostate—in as little as 22 minutes. The company reports that 6% of their members have had potential cancer identified through their scans. Ezra offers multiple scan tiers ranging from a basic MRI scan ($999) to comprehensive packages including spine, musculoskeletal, and neurological assessments ($3,999), as well as specialized CT scans for heart and lung screening. The service is designed to be fast, affordable, and accessible, with results delivered within 7-10 days and interpreted by radiologists. Ezra uses FDA-cleared AI image enhancement technology and provides detailed reports with actionable findings. The company emphasizes early detection, noting that early-stage cancer has an 80% survival rate compared to less than 20% for late-stage cancer. Scans may be eligible for HSA/FSA reimbursement, and the company offers flexible monthly payment plans. Ezra partners with imaging centers across multiple locations and serves both individual consumers and corporate wellness programs.
Company description Ezra official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Cloud Saas · Other deployment with recorded integration context.
Company milestones
United with Function to offer integrated preventive health screening services. Partnership program generating $10,000+ monthly revenue per imaging center location. 40% member return rate for annual scans.
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Platform for physicians to access and review patient scan results
5-minute low-dose CT scan measuring coronary artery calcium score for cardiovascular risk assessment
3-minute low-dose CT scan for early detection of lung cancer, nodules, and emphysema
22-minute full-body MRI screening for early cancer detection in up to 13 organs
Comprehensive 2-session MRI with brain age analysis, musculoskeletal assessment, and body composition profiling
47-minute MRI scan including spine coverage for spinal lesions, herniated discs, and degenerative changes
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
International journal of radiation oncology, biology, physics · Jul 1, 2026
Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.Oral oncology · Jul 1, 2026
Longevity and Volume Expansion of Hyaluronic Acid Dermal Fillers: A Cross-sectional 3-dimensional Magnetic Resonance Imaging Study.Plastic and reconstructive surgery. Global open · Jul 1, 2026
Toward mechanistic virtual immune cells.Nature biotechnology · Jun 25, 2026
Public support for mitochondrial donation: an Australian knowledge and attitudes study.Reproductive biomedicine online · Jun 1, 2026
Contours and Confusions: A Review of Malar Mounds, Malar Edema, and Festoons.The Journal of craniofacial surgery · May 21, 2026
Clinical validation
NCT03603223 · Mentioned · RECRUITING
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental VitiligoNCT07431177 · Mentioned · RECRUITING
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)NCT07116967 · Mentioned · RECRUITING
Autologous Platelet Concentrate (APC) in Intrabony DefectsNCT04254861 · Mentioned · RECRUITING
Periodontal Assessment of a Bariatric Care PopulationNCT04851470 · Mentioned · RECRUITING
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029 · Mentioned · RECRUITING
Regulatory
No linked records are currently available.
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Percentage of members who had potential cancer identified through Ezra scans
Early cancer detection vs <20% for late-stage cancer (American Cancer Society data)
Time to receive full Ezra Report after scan completion
Detection of stage 3 kidney tumors on both kidneys in asymptomatic lifelong athlete
Early detection gave patient chance for longer life according to physician
Partnership to provide MRI screening services and generate cash-pay revenue
245 scans in 2025, 94 NPS score, steady volume increase, critical findings enabling early intervention
Proactive MRI scans caught cancer early twice
Early detection enabled successful treatment and health reclamation on two separate occasions
Early detection of large brain tumor through preventive MRI screening
Tumor discovered 5-10 years earlier than it would have been without screening, potentially adding years of quality of life
Partnership to deliver high-quality imaging with elevated patient experience
125 scans in 2025, 94 NPS score, 4 Ezra sites, major value-driver for organization
05 · Leadership
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Recent articles published on Ezra's official website.
No Company updates are currently listed.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.